Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About RenovaCare, Inc.
RenovaCare, Inc. operates as a development stage company, which engages in the research, development, and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The company is headquartered in Scottsdale, Arizona and currently employs 1 full-time employees. The company went IPO on 2000-08-08. The firm is focused on the research, development and commercialization of autologous cellular therapies for the regeneration of human organs and tissues. The Company’s product under development targets the skin. The firm's flagship technology, the CellMist System, renders single-cell suspensions of tissue-specific pluripotent cells from donor tissues through sequential protease digestions. The RenovaCare CellMist System facilitates healing of wounds or other afflicted tissues when applied as a gentle cell mist using the RenovaCare SkinGun. The Company’s CellMist System consists of the CellMist cell suspension derived by enzymatic digestion of a patient’s own skin tissue applied topically with its electronic SkinGun spray device to deliver a single-cell mist onto the patient's burn wound. The firm's wholly owned subsidiary is RenovaCare Sciences Corp.
Industry: Surgical & Medical Instruments & Apparatus Peers: Adhera Therapeutics, Inc. U.S. Stem Cell, Inc. BURZYNSKI RESEARCH INSTITUTE INC POLARITYTE, INC. LadRx Corp TENAX THERAPEUTICS, INC. Scopus BioPharma Inc.
